Korro Bio (KRRO) Competitors $13.98 -0.89 (-5.99%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRRO vs. ERAS, ABVX, BNTC, KMDA, PGEN, ITOS, RVNC, FULC, CKPT, and VIGLShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Erasca (ERAS), ABIVAX Société Anonyme (ABVX), Benitec Biopharma (BNTC), Kamada (KMDA), Precigen (PGEN), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. Its Competitors Erasca ABIVAX Société Anonyme Benitec Biopharma Kamada Precigen iTeos Therapeutics Revance Therapeutics Fulcrum Therapeutics Checkpoint Therapeutics Vigil Neuroscience Erasca (NASDAQ:ERAS) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has higher earnings and valuation, ERAS or KRRO? Korro Bio has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.62-2.47Korro Bio$4.82M27.23-$81.17M-$9.44-1.48 Does the MarketBeat Community believe in ERAS or KRRO? Korro Bio received 2 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 100.00% of users gave Korro Bio an outperform vote while only 73.17% of users gave Erasca an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes3073.17% Underperform Votes1126.83% Korro BioOutperform Votes32100.00% Underperform VotesNo Votes Which has more volatility and risk, ERAS or KRRO? Erasca has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Do analysts rate ERAS or KRRO? Erasca presently has a consensus price target of $4.57, suggesting a potential upside of 198.79%. Korro Bio has a consensus price target of $102.43, suggesting a potential upside of 632.68%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Is ERAS or KRRO more profitable? Erasca's return on equity of -42.26% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Korro Bio N/A -50.25%-38.48% Does the media prefer ERAS or KRRO? In the previous week, Korro Bio had 5 more articles in the media than Erasca. MarketBeat recorded 7 mentions for Korro Bio and 2 mentions for Erasca. Erasca's average media sentiment score of 1.80 beat Korro Bio's score of 1.27 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ERAS or KRRO? 67.8% of Erasca shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 14.4% of Erasca shares are held by insiders. Comparatively, 4.6% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKorro Bio beats Erasca on 10 of the 17 factors compared between the two stocks. Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.64M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-1.488.6727.1419.96Price / Sales27.23262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.666.597.064.69Net Income-$81.17M$143.75M$3.23B$248.14M7 Day Performance13.20%3.72%2.67%2.39%1 Month Performance-12.52%11.01%8.82%6.05%1 Year Performance-67.19%3.87%31.44%13.60% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio3.5686 of 5 stars$13.98-6.0%$102.43+632.7%-64.8%$139.64M$4.82M-1.4870Positive NewsAnalyst RevisionGap DownERASErasca2.774 of 5 stars$1.43+1.8%$4.57+220.8%-32.4%$403.68MN/A-1.72120Positive NewsABVXABIVAX Société Anonyme1.9918 of 5 stars$6.35+5.5%$31.00+388.2%-47.3%$402.82MN/A0.0061Analyst RevisionGap UpHigh Trading VolumeBNTCBenitec Biopharma2.261 of 5 stars$15.61+1.6%$24.71+58.3%+120.8%$399.62M$80K-10.3420KMDAKamada3.8224 of 5 stars$6.90+0.7%$14.67+112.6%+36.3%$396.61M$167.24M24.64360Positive NewsShort Interest ↑PGENPrecigen4.1513 of 5 stars$1.33+0.8%$5.50+313.5%-8.5%$392.59M$4.20M-2.42190News CoveragePositive NewsAnalyst ForecastAnalyst RevisionITOSiTeos Therapeutics3.8669 of 5 stars$10.01-0.1%$15.86+58.4%-38.7%$383.51M$35M-3.1890Insider TradeHigh Trading VolumeRVNCRevance Therapeutics2.5923 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500FULCFulcrum Therapeutics0.4366 of 5 stars$6.96+1.2%$6.29-9.7%-7.7%$375.69M$80M-22.45100Analyst RevisionCKPTCheckpoint Therapeutics2.5412 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210VIGLVigil Neuroscience4.0561 of 5 stars$7.93+0.5%$10.80+36.2%+71.6%$370.11MN/A-3.8540Positive News Related Companies and Tools Related Companies Erasca Alternatives ABIVAX Société Anonyme Alternatives Benitec Biopharma Alternatives Kamada Alternatives Precigen Alternatives iTeos Therapeutics Alternatives Revance Therapeutics Alternatives Fulcrum Therapeutics Alternatives Checkpoint Therapeutics Alternatives Vigil Neuroscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRRO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRRO Stock Free KRRO Stock Alerts